Alembic Pharmaceuticals Limited (APLLTD) AI Stock Analysis

• Market Cap: ₹184.03B
• Dividend Yield: 1.17%
• Average Volume (3M): 5.51K
• Price to Earnings (P/E): 30.5
• Beta (1Y): 0.91
• Revenue Growth: 8.20%
• EPS Growth: -4.26%
• Country: IN
• Employees: 14,858
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.90
• Shares Outstanding: 196,563,130
• 10 Day Avg. Volume: 3,656
• 30 Day Avg. Volume: 5,511
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹931.67
• Price Target Upside: -0.49% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 53 Neutral
• Price Target: ₹950.00 ▲(1.47% Upside)

Alembic Pharmaceuticals faces a mixed outlook. Strong revenue growth is offset by cash flow challenges and high leverage. Technical indicators suggest bearish momentum, and valuation metrics indicate potential overvaluation. The absence of earnings call and corporate events data limits further insights.

Alembic Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Alembic Pharmaceuticals Limited (APLLTD) is a leading pharmaceutical company headquartered in India, renowned for its expertise in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in the generic pharmaceuticals sector, providing a wide range of formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments including cardiology, neurology, diabetes, gastroenterology, and more. APLLTD's core services include the development of high-quality medicines that comply with stringent regulatory standards, catering to both domestic and international markets.

How the Company Makes Money

Alembic Pharmaceuticals Limited makes money primarily through the sale of its pharmaceutical products, which include both generic formulations and active pharmaceutical ingredients (APIs). The company generates revenue from domestic sales in India as well as through exports to international markets such as the United States, Europe, and other regions. Key revenue streams include the mass production and distribution of generic drugs, which are sold to wholesalers, pharmacies, and healthcare providers. Additionally, APLLTD engages in contract manufacturing and out-licensing arrangements, where it partners with other pharmaceutical companies to produce or distribute products, enhancing its market reach and distribution capabilities. The company also invests in research and development to innovate and expand its product portfolio, ensuring a steady pipeline of new and competitive products to sustain its revenue growth.

Alembic Pharmaceuticals Limited Financial Statement Overview

Summary

Alembic Pharmaceuticals shows strong revenue growth and profitability improvements, but faces challenges with cash flow management and rising leverage.

Income Statement

Alembic Pharmaceuticals shows strong gross profit margins over the years, with a notable improvement in revenue and EBIT margins in the recent period. However, the net profit margin has experienced some fluctuations, indicating potential cost management issues. The consistent revenue growth rate is a positive indicator of the company's expanding market presence.

Balance Sheet

The balance sheet reveals a healthy equity base, reflected in a strong equity ratio. The debt-to-equity ratio increased in the latest period, which could indicate rising leverage and potential risk. However, the return on equity remains robust, suggesting efficient use of shareholders' funds.

Cash Flow

The cash flow statement highlights a decline in free cash flow due to increased capital expenditures. The operating cash flow to net income ratio is lower, indicating less cash generation from operations. The negative free cash flow to net income ratio suggests challenges in converting profits into cash.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	66.72B	66.72B	62.29B	56.53B	52.32B	52.76B
Gross Profit	44.30B	48.79B	22.69B	39.44B	35.09B	37.55B
EBITDA	10.51B	10.08B	9.62B	7.11B	9.25B	15.68B
Net Income	5.83B	5.83B	6.16B	3.42B	5.21B	11.46B
Balance Sheet
Total Assets	77.73B	77.73B	64.46B	61.83B	71.22B	67.09B
Cash, Cash Equivalents and Short-Term Investments	901.00M	901.00M	1.20B	921.20M	610.90M	2.85B
Total Debt	12.57B	12.57B	5.13B	7.22B	7.17B	5.84B
Total Liabilities	25.83B	25.83B	16.27B	18.12B	18.84B	16.42B
Stockholders Equity	51.91B	51.91B	48.18B	43.70B	52.38B	51.28B
Cash Flow
Free Cash Flow	0.00	-4.76B	4.76B	2.81B	1.27B	8.04B
Operating Cash Flow	0.00	879.70M	8.03B	7.24B	5.52B	14.63B
Investing Cash Flow	0.00	-5.68B	-3.21B	-4.48B	-3.72B	-8.39B
Financing Cash Flow	0.00	4.44B	-4.38B	-2.62B	-2.17B	-5.97B

Alembic Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 936.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APLLTD, the sentiment is Negative. The current price of 936.25 is below the 20-day moving average (MA) of 965.32, below the 50-day MA of 976.33, and below the 200-day MA of 949.96, indicating a bearish trend. The MACD of -4.67 indicates Negative momentum. The RSI at 40.23 is Neutral, neither overbought nor oversold. The STOCH value of 45.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:APLLTD.

Alembic Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	74 Outperform	₹153.21B	9.23		0.58%	4.14%	3.72%
JBCHEPHARM	72 Outperform	₹268.55B	38.99		0.90%	11.56%	16.30%
MARKSANS	69 Neutral	₹78.49B	22.42		0.45%	16.94%	4.90%
GLAXO	65 Neutral	₹472.34B	49.71		1.93%	6.65%	48.47%
JUBLPHARMA	56 Neutral	₹165.92B	37.04		0.48%	8.12%	-16.64%
APLLTD	53 Neutral	₹184.03B	30.51		1.17%	8.20%	-4.26%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%

Alembic Pharmaceuticals Limited Corporate Events

Alembic Pharmaceuticals Updates RTA Contact Details

Alembic Pharmaceuticals Limited has announced a change in the email and website address of its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update is crucial for stakeholders as it ensures seamless communication and service requests, reflecting the company’s commitment to maintaining efficient operations and stakeholder engagement.